Despite advances in surgical techniques, chemo-drugs, and molecular-targeted drugs (e.g., bevacizumab and cetuximab targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), respectively) [4], the number of CRC patients is increasing progressively [5,6]. This evidence concerns the gene EGFR and colorectal carcinoma.